We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+26.72%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.13B
AUM Growth
+$109M
Cap. Flow
-$57.7M
Cap. Flow %
-5.12%
Top 10 Hldgs %
41.36%
Holding
140
New
44
Increased
20
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$38.4M
2
LLY icon
Eli Lilly
LLY
+$37.9M
3
ONCR
Oncorus, Inc.
ONCR
+$20.9M
4
SGTX
Sigilon Therapeutics, Inc. Common Stock
SGTX
+$19.8M
5
CCCC icon
C4 Therapeutics
CCCC
+$12.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$56.2M
2
ABBV icon
AbbVie
ABBV
+$43.2M
3
AMGN icon
Amgen
AMGN
+$28M
4
FOLD
Amicus Therapeutics
FOLD
+$20M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 67.85%
2 Technology 8.78%
3 Industrials 3.15%
4 Consumer Discretionary 1.89%
5 Communication Services 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
51
DELISTED
Verona Pharma
VRNA
$7.24M 0.64%
1,033,603
+33,603
+3% +$227K
BLSA
52
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$6.89M 0.61%
+625,000
New +$6.7M
AMZN icon
53
Amazon
AMZN
$2.92T
$6.71M 0.6%
41,220
-35,180
-46% -$5.61M
MRTX
54
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.54M 0.58%
29,779
-3,221
-10% -$696K
YMAB
55
DELISTED
Y-mAbs Therapeutics
YMAB
$6.49M 0.58%
131,016
-265,505
-67% -$12.3M
ORIC icon
56
Oric Pharmaceuticals
ORIC
$1.15B
$6.17M 0.55%
+182,200
New +$5.23M
FOLD
57
DELISTED
Amicus Therapeutics
FOLD
$6.14M 0.54%
265,753
-977,797
-79% -$20M
KRYS icon
58
Krystal Biotech
KRYS
$10.1B
$6.06M 0.54%
101,044
-83,529
-45% -$4.17M
DCPH
59
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.91M 0.52%
103,565
-240,400
-70% -$14.2M
IOVA icon
60
Iovance Biotherapeutics
IOVA
$1.82B
$5.91M 0.52%
127,289
-125,711
-50% -$4.99M
ALLT icon
61
Allot
ALLT
$372M
$5.61M 0.5%
533,192
-512,145
-49% -$5.19M
NVMI
62
Nova
NVMI
$12.4B
$5.51M 0.49%
+78,113
New +$4.86M
PRAX icon
63
Praxis Precision Medicines
PRAX
$8.58B
$5.5M 0.49%
+6,667
New +$3.89M
ARKO icon
64
ARKO Corp
ARKO
$896M
$5.4M 0.48%
+600,000
New +$5.9M
VTGN icon
65
VistaGen Therapeutics
VTGN
$9.89M
$5.29M 0.47%
+90,833
New +$2.32M
IONS icon
66
Ionis Pharmaceuticals
IONS
$8.6B
$5.19M 0.46%
+91,800
New +$4.57M
CNCE
67
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$4.85M 0.43%
384,039
+74,039
+24% +$844K
GRTX
68
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.78M 0.42%
467,662
-1,583
-0.3% -$17.3K
DRNA
69
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.78M 0.42%
216,980
+17,000
+9% +$374K
DMRA
70
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.78B
$4.67M 0.41%
+15,671
New +$5.83M
EPIX
71
DELISTED
ESSA Pharma
EPIX
$4.66M 0.41%
390,200
+140,200
+56% +$987K
KALV
72
DELISTED
KalVista Pharmaceuticals
KALV
$4.56M 0.4%
240,140
– –
FROG icon
73
JFrog
FROG
$9.66B
$4.55M 0.4%
72,377
-23,038
-24% -$1.61M
STRO icon
74
Sutro Biopharma
STRO
$401M
$4.38M 0.39%
+20,160
New +$3.34M
NAUT icon
75
Nautilus Biotechnolgy
NAUT
$124M
$4.34M 0.39%
400,000
– –
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sphera Funds Management held 140 positions worth $1.13B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management withdrew a net $57.7M in Q4 2020, closing 30 positions and reducing 33 holdings. Its most notable exit was Sanofi, an estimated $56.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Bristol-Myers Squibb worth $38.8M.

  • Sphera Funds Management's largest Q4 2020 buy was Bristol-Myers Squibb: 625,000 shares worth $38.8M.
  • Sphera Funds Management added most to Eli Lilly in Q4 2020, an estimated $37.9M increase.
  • Sphera Funds Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $43.2M.
  • Sphera Funds Management fully exited Sanofi in Q4 2020, selling an estimated $56.2M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $1.13B portfolio in Q4 2020.
  • Sphera Funds Management opened 44 new positions and closed 30 in Q4 2020.
  • Sphera Funds Management's portfolio value rose 11% quarter-over-quarter to $1.13B.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.